Method for treating bronchial asthma cases

FIELD: medicine.

SUBSTANCE: method involves administering intravenous hemodesis injections at a dose of 200 ml every other day as a part of traditional therapy after having studied patient immunity status. The total treatment course requires 600-1000 ml for 3-5 infusions. Rusam is concurrently administered at a dose of 20 mg once a day with 4-5 days long pauses. The total treatment course requires 600-800 mg of the drug.

EFFECT: enhanced effectiveness of selective treatment directed to given immune system chains.

 

The invention relates to medicine, namely to pulmonology.

Bronchial asthma is often accompanied by the development of secondary immune deficiency, which manifests itself, first of all, the failure of T - and b-immunity (Amesco, Wmemcmp, Aviroop and other Immunopathology and immunotherapy nonspecific inflammatory diseases of the lungs. - Voronezh: ASD, 2000. - 440 S.).

In pharmacological immune known method of treatment of mixed forms of bronchial asthma using gemodeza, which is administered intravenously at a dose of 400 ml of 2 consecutive days (Aguchi and other Immunotherapy in pulmonology. - M.: Medicine, 1989. - P.48-50).

However, the lack of therapy gemodeza consists in the possibility of complications from heart, kidney, liver, allergic reactions, given that contraindications to the drug are idiosyncrasy and decompensated heart failure.

Secondly, the empirical use of separate modulators, for example gemodeza, often does not lead to the reduction or complete elimination of secondary immune deficiency (Amesco, Wmemcmp, Yevseyev, Vagorovskiy, Aviroop. 1000 formulas of clinical immunology. - M.: Medicine for all. - 2003. - 336 S.), which is one of the major drawbacks of this kind of therapy.

Thirdly, lack of monotherapy with immunomodulators is that the preservation of secondary immune deficiency in patients with bronchial asthma leads to chronicity of the process and the frequent recurrence of the disease, which significantly reduces the effectiveness of conventional baseline treatment of mixed form of bronchial asthma.

The technical result of the invention is to improve the efficiency of conventional baseline treatment of bronchial asthma.

The technical result is achieved by the fact that prompted gemodez intravenously at a dose of 200 ml a day for treatment - 600-1000 ml (3-5 infusions) with the parallel introduction of rusama intramuscularly at a dose of 200 mg 1 time per day 4-5 days per course of treatment is 600-800 mg

The combination of drugs was included in the conventional therapy of illness 3-5 days from the time of admission, after research of the immune status and determine the extent and nature of secondary immune deficiency (Amesco, Wmemcmp, Aviroop, Laevigata. Handbook of operational information on clinical immunology and Allergology. - Voronezh: Publishing house of Voronezh state University, 1997. - 161 C.).

The rationale of this scheme eliminate secondary immune deficiency in a mixed form of asthma is a need for a study of a particular drug to predict his actions in terms of INR is esta various breakdowns of the immune system (Genesareth, Equilenin. Immune stimulants. - M.: Medicine, 1985. - 256 S.).

Under the combination of immunomodulator therapy understand sequential or simultaneous application of several immunomodulating agents with different mechanisms of action, with the aim of eliminating immunological disorders (Amesco, Wmemcmp, Aviroop. Clinical immunology / edited Averella. - M.: MIA. - 1999. - 604 S.).

Indications for combined immune disorders are the following: 1) chronic (more than three months) pathologic process, frequent relapses, related complications and secondary conditions; 2) the expressed intoxication syndrome, metabolic, protein loss by the kidneys and so on; 3) unsuccessful immunomodulating therapy individual drug within one month; 4) high degree of immune deficiency (third) or combined lesions of T - and b-immunity, T and b-lymphocytes and macrophages, mixed disorders of the immune system, stimulation of one and decrease the other indicators of the level of norms. The basis for selecting the components of the combined modulation are particularly disorders of the immune status and the combined action of modulators (Amesco, Wmemcmp, Yevseyev, Aviroop. Non-drug immunotherapy. - M: NAT. Acad. mycologists who, 2002. - 264 S.).

The efficiency of complex treatment of bronchial asthma with the inclusion of a combination of gemodeza with RusAtom can be illustrated by the following example.

Example. Statement of the case history No. 1471. Patient E., 20, was hospitalized in GKB №20 in Voronezh with 13.04.2004, 28.04.2004, diagnosis: bronchial asthma, mixed shape, moderate, corticotomy, acute stage. DNI.

From anamnesis morbi: suffers from bronchial asthma for 6 years. Steroid hormones intravenously and polcortolon at a dose of 2 to 4 tablets per day, taken occasionally, inhaled steroids (beklager) gets in the last 5 years. Currently taking polcortolon dose of 2 pills a day and inhaled corticosteroids (beklager 2 doses 2 times a day). At admission she complained of asthma, up to 3-4 times a day, mostly at night, bad intractable reception of berodual, shortness of breath when climbing on the 3rd floor, hesitant breath, dry cough, weakness. Objectively: General condition is satisfactory. NPV=20-22 per minute. Thorax common forms, both halves evenly engage in the act of breathing. Percussion - pulmonary sound. Lung auscultation: breath weak, scattered dry wheezing in all lung fields, exhale longer. The pulse was 80 beats per minute, rhythmic, UD is vetveredeling filling and voltage. BP - 120/80 mm Hg Abdomen is soft, painless on palpation. Liver and spleen not palpable. Peripheral edema no.

Instrumental and laboratory data: complete blood count and urine without pathology; ECG sinus rhythm, the EOS is not rejected; FER - significant violations of bronchial obstruction in obstructive type.

Immunological examination of the patient revealed a second degree of immune deficiency. Treatment: aminophylline +0.9% solution of sodium chloride, berodual, beklager, dexamethasone intravenously, polcortolon. For correction of immune deficiency were given a combination of immunomodulators, first introduced gemodez dose of 200 ml a day for treatment - 600-1000 ml (3-5 infusions) in parallel with the use of rusama intramuscularly at a dose of 200 mg 1 time per day 4-5 days per course of treatment is 600-800 mg Treatment was started 2 days after admission. After a week from the beginning of the immunomodulation of the patient's condition has improved significantly, asthma, cough stopped, wheezing disappeared. Was discharged with improvement on the 15-day hospital stay. In this case, the removal of the main symptoms of the disease occurred by the middle of the second week of inpatient treatment, indicating good effect of combined immunotherapy.

Inclusion in the treatment of bronchial the asthma combination gemodeza with RusAtom installed, the use of combinations of drugs increases the effectiveness of conventional basic therapy of mixed form of bronchial asthma. Composition gemodeza with RusAtom accompanied by more rapid in comparison with usual care, on average, 2-3 days, the normalization of the main manifestations of bronchial asthma, which allows to reduce the time of stay of patients in hospital for 1-2 days.

The method of treatment of bronchial asthma by traditional therapy, including the introduction gemodeza, wherein prompted gemodez intravenously at a dose of 200 ml through day treatment 600-1000 ml (3-5 infusions) with the parallel introduction of rusama intramuscularly at a dose of 200 mg 1 time per day, 4-5 days of treatment 600-800 mg



 

Same patents:

FIELD: medicine, surgery, urology.

SUBSTANCE: one should apply bactisporin probiotic preparation introduced per os at 1-10 x 109 microbial cells twice or thrice for 10-20 d in combination with staphylo-proteic-pyocyanic adsorbed (SPPA) vaccine; moreover, the mentioned combination of preparation should be applied, also, for instillation of wounds, serous cavities, cavities of urinary and biliary ducts at the quantity of 1-5 x 109 microbial cells in isotonic sodium chloride solution. The present innovation provides better humoral and cellular immunity to already developed infectious process, moreover, combined application of SPPA vaccine and bactisporin leads to increased body immune response to antigens of associated vaccine at the background of secondary immunodeficient state induced by infectious process.

EFFECT: higher efficiency of therapy.

1 cl, 5 ex, 3 tbl

The invention relates to biotechnology and can be used for the treatment and prevention of disease associated with infection by Streptococcus or G+ bacteria

The invention relates to medicine, namely to Allergology, and can be used for the treatment of atopic dermatitis

The invention relates to the field of veterinary medicine
The invention relates to the field of veterinary Microbiology

The invention relates to medicine, experimental gynecology, and can be used for modeling chronic inflammation of the uterus

The invention relates to medicine, specifically to pharmacology

The invention relates to medicine, in particular for inhalation preparations, with the ability to resolve the obstruction (narrowing of the bronchi) by removing the first and second phase of allergic airway inflammation and spasm of the smooth muscles of the bronchi

The invention relates to biotechnology, in particular to a method for toxoid for specific prophylaxis of diseases staphylococcal etiology

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a pharmaceutical composition and a method for it preparing. The composition comprising effective doses of hyaluronic acid, glycyrrhetinic acid as active components and polyvinylpyrrolidone is used in treatment of morbid inflammatory and ulcerous states of moisture epithelial surfaces, such as mucosa inflammation and Behchet's syndrome. The composition shows favorable effect due to its moistening action.

EFFECT: valuable medicinal and pharmaceutical properties of composition.

6 cl, 3 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with ways for purifying blood plasma in burnt patients followed by applying the plasma obtained either while carrying out the next plasmapheresis or as independent transfusion medium. For this purpose, it is necessary to carry out plasmapheresis in burnt patients. Heparin should be added into plasma removed during plasmapheresis and, additionally, hemodesis, followed by incubation at +4° C for about 5-18 h, then it should be centrifuged for depositing cryoprecipitate. The innovation suggested enables to alter conditions of cryoprecipitation so, that it is possible to increase precipitation of fibrinogen and fibrin-monomeric complexes, the quantity of which is sharply observed in burnt patients.

EFFECT: higher efficiency of purification.

1 tbl

FIELD: medicine.

SUBSTANCE: method involves introducing means containing heavy elements into tumor and expose it to X-ray radiation. A heavy chemical element having number of 53, 55-83 is used. The means contains one or several of said elements with additional ligand introduced as iminodiacetic acid or its derivatives or crownethers or porphyrins and a water-soluble polymer. The means is introduced in systemic or direct way into tumor with following X-ray irradiation of power of 10-200 keV being applied.

EFFECT: increased photon therapy dose concentrated in tumor tissue with concurrently reduced radiation exposure upon the unaffected tissues.

4 cl, 4 dwg, 6 tbl

FIELD: otorhinolaryngology.

SUBSTANCE: method consists in that, once a day, maxillary sinus is punctured, washed with 0.01% betadine solution and, after that, 10 ml of 0.1% betadine solution is injected into sinus. Treatment course comprises 3-4 punctures.

EFFECT: increased acute sinusitis treatment efficiency in absence of general antibacterial therapy due to simultaneous action of betadine on bacterial and viral constituents of pathogenic microflora.

FIELD: medicine, ophthalmology.

SUBSTANCE: invention proposes a composition for treatment and storage of soft contact lens that comprises cetyl pyridinium chloride, polyethylene oxide of molecular mass 400 Da, ethylenediaminetetraacetic acid disodium salt, sodium hydrogen phosphate dodecahydrate, sodium dihydrogen phosphate dihydrate and water taken in the definite ratios by wt.-%. Invention provides reducing toxicity and enhances disinfecting and clearing properties of composition used for treatment and storage of soft contact lens.

EFFECT: improved and valuable properties of composition.

2 tbl, 3 ex

FIELD: medicine, ophthalmology, pharmacology, pharmacy.

SUBSTANCE: invention proposes a new agent for applying in therapy of inflammatory diseases of eye anterior site, namely, the silver-containing preparation "Argogel" "Argogel" represents argovite dispersion in polyethylene oxide gel. The preparation shows an antibacterial and virucidal effect and gel base shows additional keratoplastic effect. Invention can be used in therapy of conjunctivitis and retina suppurative ulcers.

EFFECT: valuable medicinal properties of agent.

4 ex

FIELD: organic synthesis.

SUBSTANCE: invention provides novel triterpenoid derivatives having general formula:

(I), wherein, as polymer carrier, are used water-soluble copolymers of N-vinylpyrrolidone with α,β-(methyl)acrylic acid alkyl esters and quaternary ammonium salts thereof having general formula: (II), in which formulas A represents triterpenoid residue belonging to series of acids: betulinic {1}, betulonic {2}, glycyrrhetinic {3}, glycyrrhisic {4}, ursolic {5}, ursonic {6}, oleanolic {7}, oleanonic {8}, meristothropic {9}, diketomeristothropic {10}, macedonic {11}, diketomacedonic {12},equinocystic {13}, or mixture of above-indicated carboxyl-containing triterpenoids, where R1 and R2 are hydrogen or methyl; R3 methyl or ethyl; R4 is C6-C16-alkyl; Hal is iodine, bromine, or chlorine atom; k = 65-95 mol %; l = 0.1-34 mol %; n = 0.5-5.4 mol %; molecular weight is equal to (7-100)·103. Polymer derivatives of above-defined triterpenoids are prepared by reaction of terpolymer II, wherein k = 65-95 mol %; l = 0.1-34 mol %; x = 1.0-34.9 mol %; R1-R4, Hal and molecular weight as above. Reaction is carried out in organic solvent at concentration of terpolymer 1 to 30%, concentration of triterpenoid 0.05 to 3.4%, and molar ratio of motif containing quaternary nitrogen to triterpenoid between 1 and 10. Products are isolated by removing solvent.

EFFECT: expanded synthetic possibilities.

FIELD: pharmaceutics.

SUBSTANCE: the innovation deals with manufacturing remedies to prevent wound suppuration based upon polymeric matrix and antimicrobial substance due to mixing components in solution, forming the film to obtain a powder-like medicinal form by providing the safety of antimicrobial activity of medicinal preparation. The obtained remedy is completely biodestructed in the body and requires no repeated operation on its removal after the end of tissue regeneration processes.

EFFECT: higher efficiency of manufacturing.

1 cl, 3 ex, 1 tbl

The invention relates to the field of pharmaceuticals, namely, to a method for plasma-solution, and can be used in clinical medicine and in the pharmaceutical industry
The invention relates to medicine, namely to addiction

FIELD: pharmaceutics.

SUBSTANCE: the innovation deals with manufacturing remedies to prevent wound suppuration based upon polymeric matrix and antimicrobial substance due to mixing components in solution, forming the film to obtain a powder-like medicinal form by providing the safety of antimicrobial activity of medicinal preparation. The obtained remedy is completely biodestructed in the body and requires no repeated operation on its removal after the end of tissue regeneration processes.

EFFECT: higher efficiency of manufacturing.

1 cl, 3 ex, 1 tbl

Up!